BACKGROUND/ OBJECTIVE: Left ventricular (LV) circumferential or longitudinal shortening may be impaired in patients with type 2 diabetes mellitus (DM). In the present study, patients with type 2 DM without myocardial ischemia and combined impairment of circumferential and longitudinal (C+L) shortening were studied to assess the prevalence and factors associated with this condition. METHODS: Data from 386 patients with type 2 DM enrolled in the SHORTening of midWall and longitudinAl left Ventricular fibers in diabEtes study were analyzed. One hundred twenty healthy subjects were used to define C+L dysfunction. Stress-corrected midwall shortening and mitral annular peak systolic velocity were considered as indexes of C+L shortening and classified as low if <89% and <8.5 cm/s, respectively (10th percentiles of controls). RESULTS: Combined C+L dysfunction was detected in 66 patients (17%). The variables associated with this condition were lower glomerular filtration rate (OR 0.98 [95% CI 0.96 to 0.99], greater LV mass (OR 1.05 [95% CI 1.02 to 1.08]), high pulmonary artery wedge pressure (OR 1.23 [95% CI 1.04 to 1.44]) and mitral annular calcifications (OR 3.35 [95% CI 1.71 to 6.55]). Considering the entire population, the relationship between stress-corrected midwall shortening and peak systolic velocity was poor (r=0.20), and the model was linear. The relationship was considerably closer and nonlinear in patients with combined C+L dysfunction (r=0.61; P<0.001), having the best fit by cubic function. CONCLUSIONS: Combined C+L dysfunction was present in one-sixth of patients with type 2 DM without myocardial ischemia. This condition was associated with reduced renal function, worse hemodynamic status and structural LV abnormalities, and may be considered a preclinical risk factor for heart failure.
BACKGROUND/ OBJECTIVE: Left ventricular (LV) circumferential or longitudinal shortening may be impaired in patients with type 2 diabetes mellitus (DM). In the present study, patients with type 2 DM without myocardial ischemia and combined impairment of circumferential and longitudinal (C+L) shortening were studied to assess the prevalence and factors associated with this condition. METHODS: Data from 386 patients with type 2 DM enrolled in the SHORTening of midWall and longitudinAl left Ventricular fibers in diabEtes study were analyzed. One hundred twenty healthy subjects were used to define C+L dysfunction. Stress-corrected midwall shortening and mitral annular peak systolic velocity were considered as indexes of C+L shortening and classified as low if <89% and <8.5 cm/s, respectively (10th percentiles of controls). RESULTS: Combined C+L dysfunction was detected in 66 patients (17%). The variables associated with this condition were lower glomerular filtration rate (OR 0.98 [95% CI 0.96 to 0.99], greater LV mass (OR 1.05 [95% CI 1.02 to 1.08]), high pulmonary artery wedge pressure (OR 1.23 [95% CI 1.04 to 1.44]) and mitral annular calcifications (OR 3.35 [95% CI 1.71 to 6.55]). Considering the entire population, the relationship between stress-corrected midwall shortening and peak systolic velocity was poor (r=0.20), and the model was linear. The relationship was considerably closer and nonlinear in patients with combined C+L dysfunction (r=0.61; P<0.001), having the best fit by cubic function. CONCLUSIONS: Combined C+L dysfunction was present in one-sixth of patients with type 2 DM without myocardial ischemia. This condition was associated with reduced renal function, worse hemodynamic status and structural LV abnormalities, and may be considered a preclinical risk factor for heart failure.
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: Giovanni Cioffi; Pompilio Faggiano; Donata Lucci; Andrea Di Lenarda; Gian Francesco Mureddu; Luigi Tarantini; Paolo Verdecchia; Marco Comaschi; Carlo B Giorda; Mario Velussi; Marcello Chinali; Roberto Latini; Serge Masson; Giovanni De Simone Journal: J Hypertens Date: 2011-10 Impact factor: 4.844
Authors: Giovanni Cioffi; Carlo B Giorda; Marcello Chinali; Andrea Di Lenarda; Pompilio Faggiano; Donata Lucci; Aldo P Maggioni; Serge Masson; Gian Francesco Mureddu; Luigi Tarantini; Mario Velussi; Marco Comaschi Journal: Eur J Prev Cardiol Date: 2011-07-28 Impact factor: 7.804
Authors: Giovanni Cioffi; Luigi Tarantini; Roberto Frizzi; Carlo Stefenelli; Tiziano E Russo; Alessandro Selmi; Chiara Toller; Francesco Furlanello; Giovanni de Simone Journal: J Hypertens Date: 2011-03 Impact factor: 4.844
Authors: Laura Ernande; Ernst R Rietzschel; Cyrille Bergerot; Marc L De Buyzere; Frédéric Schnell; Laure Groisne; Michel Ovize; Pierre Croisille; Philippe Moulin; Thierry C Gillebert; Geneviève Derumeaux Journal: J Am Soc Echocardiogr Date: 2010-10-08 Impact factor: 5.251
Authors: Caroline S Fox; Martin G Larson; Ramachandran S Vasan; Chao-Yu Guo; Helen Parise; Daniel Levy; Eric P Leip; Christopher J O'donnell; Ralph B D'Agostino; Emelia J Benjamin Journal: J Am Soc Nephrol Date: 2005-12-28 Impact factor: 10.121
Authors: Kristian Wachtell; Eva Gerdts; Vittorio Palmieri; Michael H Olsen; Markku S Nieminen; Vasilios Papademetriou; Kurt Boman; Björn Dahlöf; Gerard P Aurigemma; Jens E Rokkedal; Richard B Devereux Journal: J Hypertens Date: 2010-07 Impact factor: 4.844
Authors: G de Simone; R B Devereux; M J Roman; A Ganau; P S Saba; M H Alderman; J H Laragh Journal: J Am Coll Cardiol Date: 1994-05 Impact factor: 24.094
Authors: Shi Yin Wong; Ainsley Ryan Yan Bin Lee; Aaron Hon Jiun Sia; Yu Jun Wo; Yao Hao Teo; Yao Neng Teo; Nicholas L Syn; Ching-Ching Ong; Lynette L Teo; Tiong-Cheng Yeo; Kian-Keong Poh; William K Kong; Raymond C Wong; Ching-Hui Sia Journal: Cardiovasc Drugs Ther Date: 2022-07-12 Impact factor: 3.947